Overview Request Sample Pages Request Customization Download PDF
You are viewing: Japan Bioinformatics Market analysis
Part of: Bioinformatics Market (Global)

The Japan Bioinformatics Market was valued at $823.2 Million in 2026 and projected to reach to $1606.3 Million by 2031, representing a compound annual growth rate of 14.3%. Japan's bioinformatics market is poised for accelerated growth through 2031, driven by the nation's commitment to precision medicine and genomic research excellence.

Japan Bioinformatics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Bioinformatics Market Trends and Insights

  • Japan is leveraging advanced genomic research capabilities and a strong healthcare infrastructure to drive adoption of bioinformatics solutions across pharmaceutical, clinical diagnostics, and agricultural biotechnology sectors.
  • The country's aging population and emphasis on precision medicine are accelerating demand for data-driven healthcare analytics. Japan's bioinformatics expansion is supported by significant investments in research institutions, government initiatives promoting digital health transformation, and collaborations between academic centers and industry players.
  • Japan's pharmaceutical sector is increasingly integrating bioinformatics tools for drug discovery and development, while clinical laboratories are adopting genomic sequencing platforms.
  • The 14.3% compound annual growth rate reflects Japan's commitment to biotechnology innovation and its position as a regional leader in healthcare technology adoption within Asia Pacific..

Key Market Statistics

  • CAGR (2026-2031) 14.3% CAGR
  • Market Size, 2026 ~USD 823.2 Million
  • Forecast, 2031 ~USD 1606.3 Million
  • Country Japan

Japan Bioinformatics Market Overview

Market Valuation Growth :

Japan's bioinformatics market is valued at $823.2 million in 2026 and is projected to reach $1,606.3 million by 2031, representing a robust 14.3% CAGR, outpacing the global average of 13.1%.

Genomic Research Leadership :

Japan's advanced genomic research capabilities and cutting-edge laboratory infrastructure position the country as a regional hub for bioinformatics innovation, attracting significant investment in precision medicine initiatives.

Aging Population Demand :

Japan's rapidly aging demographic drives demand for bioinformatics solutions in clinical diagnostics, personalized medicine, and disease prevention, creating sustained market expansion opportunities.

Multi-Sector Adoption :

Bioinformatics solutions are increasingly adopted across pharmaceutical R&D, clinical diagnostics, agricultural biotechnology, and academic research institutions throughout Japan, diversifying revenue streams.

Japan Bioinformatics Market Dynamics

  • The country's strong healthcare infrastructure, combined with government support for biotechnology innovation, creates a favorable environment for bioinformatics solution deployment.
  • Japan's aging population necessitates advanced diagnostic and therapeutic tools, further propelling market demand. Key growth drivers include increased pharmaceutical R&D investments, expansion of clinical genomic testing, and integration of AI-powered bioinformatics platforms in healthcare systems.
  • Japanese companies are strengthening partnerships with global bioinformatics vendors while developing indigenous solutions tailored to local healthcare needs, positioning Japan as a significant growth market within the Asia-Pacific region..

Market Ecosystem

logo-mobile

BIOINFORMATICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Provides bioinformatics solutions for genomic data analysis, next-generation sequencing (NGS) workflows, molecular diagnostics, and life science research. Its platforms support sequencing data interpretation, variant analysis, and clinical research applications. Faster genomic data analysis, improved accuracy in variant interpretation, streamlined NGS workflows, enhanced research productivity, and support for precision medicine development.
Offers integrated sequencing and bioinformatics platforms for analyzing large-scale genomic data. Its solutions support applications in oncology, inherited disease research, population genomics, and clinical diagnostics through advanced sequencing data analysis. Efficient management of complex genomic datasets, improved disease identification, faster biomarker discovery, enhanced clinical decision-making, and acceleration of personalized medicine.
Provides bioinformatics software and genomic analysis platforms for sample-to-insight workflows, molecular diagnostics, clinical research, and next-generation sequencing data interpretation. Simplified data analysis, improved workflow automation, reliable genomic insights, reduced analysis time, and enhanced support for molecular testing and precision healthcare.
Develops bioinformatics tools for genomics, transcriptomics, and molecular analysis, supporting applications such as microarray analysis, NGS data interpretation, and biomarker discovery in research and clinical settings. Improved data visualization and interpretation, increased research efficiency, accurate molecular profiling, faster discovery of biological insights, and optimized laboratory workflows.
Provides integrated bioinformatics solutions supporting clinical genomics, companion diagnostics, oncology research, and precision medicine. Its platforms enable genomic data analysis for targeted therapies and biomarker identification. Enhanced biomarker assessment, faster treatment decisions, improved diagnostic accuracy, optimized clinical workflows, and support for personalized medicine approaches.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • SANOFI
    • Merck KGaA
    • NOVARTIS
    • Pfizer Inc.

      Key Takeaways

      • Japan's bioinformatics market will nearly double from $823.2M (2026) to $1,606.3M (2031), driven by precision medicine adoption and genomic research expansion.
      • Japan's 14.3% CAGR outpaces the global average of 13.1%, reflecting strong regional demand for advanced healthcare analytics and biotechnology solutions.
      • Japan's aging demographic and emphasis on personalized treatment protocols are accelerating bioinformatics tool integration across clinical and pharmaceutical sectors.
      • Japan's robust research infrastructure and government support for digital health initiatives position the country as a key growth engine within the Asia Pacific bioinformatics market.

      Bioinformatics Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment PRECISION MEDICINE (Use Case)
      Forecast Period 2026-2031
      Growth Rate CAGR of 13.1% from 2026 to 2031
      Largest Segment SOFTWARE (Offering)
      Market Size Base Year (Billions) ~USD 18.59 (2026)
      Revenue Forecast (Billions) ~USD 34.41 (2031)
      Segments Covered Offering, Type, Function, Use Case, Sector, End User

      Japan Bioinformatics Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Offering

      • Services
      • Software

      By Type

      • Chemoinformatics Solutions
      • Cloud & Managed Bioinformatics
      • Cloud & Managed Services
      • Consulting & Custom Bioinformatics Development
      • Data Analysis & Interpretation
      • Database & Data Management
      • Drug Discovery & Target Identification
      • End-To-End Solutions
      • Gene Expression Analysis
      • Generalized Knowledge Management Tools
      • Genomics Solutions
      • Knowledge Management Tool
      • Metabolomics Solutions
      • Multi-Omics Solutions
      • Multiomics Solutions
      • Niche Point Solutions
      • Other Bioinformatics Services
      • Other Data Analysis Functions
      • Other End-To-End Solutions
      • Other Services
      • Proteomics Solutions
      • Sequence Analysis
      • Sequencing & Data Generation
      • Specialized Knowledge Management Tools
      • Transcriptomics Solutions
      • Variant Analysis

      By Function

      • Clinical Interpretation
      • Data Analysis
      • Data Visualization & Reporting
      • Multiomics Integration
      • Other Functions
      • Structural & Functional Analysis

      By Use Case

      • Biomarker Discovery
      • Clinical Diagnostics
      • Drug Discovery & Development
      • Other Use Cases
      • Precision Medicine
      • Research & Academic Applications

      By Sector

      • Animal Biotechnology
      • Environmental Biotechnology
      • Forensic Biotechnology
      • Medical Biotechnology
      • Other Sectors
      • Plant Biotechnology

      By End User

      • Academic & Research Institutes
      • Contract Research Organizations And Contract Development & Manufacturing Organizations
      • Government & Public Health Organizations
      • Hospitals & Clinical Diagnostic Laboratories
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      Target Audience

      • Pharmaceutical Companies : Japanese and international pharma firms need market intelligence to optimize R&D investments, identify bioinformatics technology partnerships, and accelerate drug discovery timelines in Japan's competitive landscape.
      • Bioinformatics Software Vendors : Solution providers require Japan-specific market data to assess market potential, understand local customer needs, develop localized offerings, and establish distribution channels in this high-growth market.
      • Healthcare Institutions & Hospitals : Japanese hospitals and diagnostic centers need market insights to evaluate bioinformatics platform investments, benchmark against peers, and align genomic testing capabilities with market trends.
      • Investment & Private Equity Firms : Investors targeting Japan's biotech sector require detailed market analysis to identify growth opportunities, evaluate portfolio companies, and make informed funding decisions in bioinformatics ventures.
      • Government & Policy Makers : Japanese government agencies and healthcare policymakers need market data to inform biotechnology strategy, allocate research funding, and develop regulatory frameworks supporting bioinformatics innovation.

      Key Companies in the Japan Bioinformatics Market

      CompanyHQOwnershipStrongest segments
      BECKMAN COULTERUnited StatesPrivate CompanyBioinformatics Software (Genomics, Multiomics, Proteomics),Bioinformatics Services (Analysis, Sequencing, Genomic Services),
      WUXI APPTECChinaPublic CompanyChemical Business,Testing Services,Biological Services,
      DANAHER CORPORATIONUnited StatesPublic CompanyDiagnostics,Life Sciences (Excl. Biotechnology),Biotechnology,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ILLUMINA, INC.United StatesPublic CompanySequencing and array-based instruments,Consumables (reagents, flow cells, library preparation, WGS and targeted kits),Services (whole-genome sequencing, genotyping, NIPT, product support, informatics services),
      QIAGEN N.V.NetherlandsPublic CompanyBioinformatics software (genomics, multiomics, proteomics),Bioinformatics-linked services (analysis, sequencing, interpretation),Non-bioinformatics consumables and instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyAgilent CrossLab,Life Sciences and Diagnostics Markets,Applied Markets,
      REVVITY, INC.United StatesPublic CompanyLife Sciences,Diagnostics,
      EUROFINS SCIENTIFICLuxembourgPublic CompanyBioinformatics-linked genomics and multiomics services,Non-informatics analytical testing (food, environment, consumer, other),
      BGI GENOMICSChinaPublic CompanySequencing and Bioinformatics Services,Clinical Testing and Precision Medicine Solutions,Mass Spectrometry and Multi-omics (Proteomics, Metabolomics, Multi-omics Integration),
      WATERS CORPORATIONUnited StatesPublic CompanyWaters Segment (LC-MS systems, consumables, and software),Materials Sciences Division (thermal analysis, rheometry, calorimetry),
      OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanySequencing instruments (MinION, GridION, PromethION),Consumables and flow cells,Software and bioinformatics services,
      10X GENOMICSUnited StatesPublic CompanySingle-cell and spatial instruments (Chromium, Chromium X Series, Visium, Xenium Analyzer, CytAssist),Consumables and reagents (microfluidic chips, slides, kits including QuantumScale),Bioinformatics software and analysis services (Cell Ranger, Loupe Browser, Xenium Explorer, associated analysis support),
      PACBIOUnited StatesPublic CompanySequencing instruments (Revio, Vega, Sequel, Onso),Consumables (SMRT cells, SMRTbell prep kits, binding and sequencing kits),Software and services (bioinformatics analysis, sequencing services, collaborations),
      SIEMENS AGGermanyPublic CompanyIndustrial Businesses (IB) - Siemens Healthineers,Industrial Businesses (IB) - Smart Infrastructure,Industrial Businesses (IB) - Digital Industries,
      SOPHIA GENETICSSwitzerlandPublic CompanySOPHiA DDM Software Platform (Genomics, Multiomics, Proteomics),Services (Analysis Support, Sequencing-Linked Informatics, Implementation),

      BECKMAN COULTER

      Beckman Coulter is a private American company founded in 1935 that employs 11,900 people. The company operates in the life sciences and diagnostics sector.

      WUXI APPTEC

      WuXi AppTec is a public Chinese company founded in 2000 with 35,584 employees. The company provides pharmaceutical and biotechnology research and development services.

      DANAHER CORPORATION

      Danaher Corporation is a public American company founded in 1969 with 59,000 employees. The company operates across multiple sectors including life sciences, diagnostics, and environmental solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a public American company founded in 1956 with 125,000 employees. The company is a leading provider of laboratory equipment, reagents, and services for life sciences research and diagnostics.

      ILLUMINA, INC.

      Illumina, Inc. is a public American company founded in 1998 with 8,625 employees. The company specializes in DNA sequencing and genetic analysis technologies.

      QIAGEN N.V.

      QIAGEN N.V. is a public Dutch company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences products.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a public American company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      REVVITY, INC.

      Revvity, Inc. is a public American company founded in 1937 with 11,000 employees. The company provides analytical instruments and life sciences solutions.

      EUROFINS SCIENTIFIC

      Eurofins Scientific is a public Luxembourg-based company founded in 1987 with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.

      BGI GENOMICS

      BGI Genomics is a public Chinese company founded in 1999 with 3,580 employees. The company specializes in genomic sequencing and genetic analysis services.

      WATERS CORPORATION

      Waters Corporation is a public American company founded in 1958 with 7,900 employees. The company manufactures analytical instruments and software for laboratory testing and research.

      OXFORD NANOPORE TECHNOLOGIES PLC

      Oxford Nanopore Technologies PLC is a public British company founded in 2005 with 1,316 employees. The company develops nanopore-based DNA and RNA sequencing technologies.

      10X GENOMICS

      10X Genomics is a public American company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions for research and diagnostics.

      PACBIO

      PacBio is a public American company founded in 2000 with 485 employees. The company develops long-read DNA sequencing technologies and systems.

      SIEMENS AG

      Siemens AG is a public German company founded in 1847 with 317,000 employees. The company operates across multiple sectors including industrial automation, energy, healthcare, and infrastructure.

      SOPHIA GENETICS

      Sophia Genetics is a public Swiss company founded in 2011 with 415 employees. The company provides AI-powered genomic analysis and interpretation software for clinical diagnostics.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise market valuation data for Japan ($823.2M in 2026) with verified 14.3% CAGR projections through 2031, enabling accurate business planning and investment decisions specific to the Japanese market.
      • Competitive Landscape Intelligence : Understand Japan-specific competitive dynamics, key players, and market positioning strategies to identify partnership opportunities and competitive advantages in this high-growth regional market.
      • Sector-Specific Insights : Access detailed analysis of bioinformatics adoption across Japanese pharmaceutical, clinical diagnostics, and agricultural biotechnology sectors to target the most lucrative market segments.
      • Demographic-Driven Opportunity Assessment : Leverage insights on Japan's aging population impact on bioinformatics demand to develop targeted solutions for personalized medicine, disease prevention, and clinical genomics applications.
      • Strategic Market Entry Planning : Utilize Japan-focused market data to develop go-to-market strategies, identify regulatory requirements, and establish partnerships with local healthcare institutions and research organizations.

      Frequently asked questions

      What is the projected size of Japan's bioinformatics market by 2031?

      Japan's bioinformatics market is projected to reach $1,606.3 million by 2031, nearly doubling from its 2026 valuation of $823.2 million.

      What is the CAGR for Japan's bioinformatics market?

      Japan's bioinformatics market is expected to grow at a compound annual growth rate of 14.3% between 2026 and 2031.

      What are the primary drivers of growth in Japan's bioinformatics market?

      Key growth drivers in Japan include precision medicine adoption, an aging population requiring advanced diagnostics, government digital health initiatives, and increased pharmaceutical R&D investments in genomic analysis.

      How does Japan's bioinformatics market growth compare to global trends?

      Japan's 14.3% CAGR exceeds the global bioinformatics market CAGR of 13.1%, indicating stronger regional growth momentum and market maturity.

      Which sectors are driving bioinformatics adoption in Japan?

      Primary sectors include pharmaceutical drug discovery, clinical diagnostics and genomic sequencing, precision medicine initiatives, and agricultural biotechnology applications.

      RESEARCH METHODOLOGY

      This research study involved the extensive use of both primary and secondary sources. It analyzed various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.

      Secondary Research

      This research study extensively used secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive, commercially focused study of the bioinformatics market, covering technical aspects and market dynamics. It also helped identify key players, market classifications, industry trends, geographic markets, and significant market developments. Additionally, a database of prominent industry leaders was compiled through secondary research.

      Primary Research

      In the primary research process, various supply-side and demand-side sources were interviewed to gather qualitative and quantitative information for this report. Primary supply-side sources included industry experts such as CEOs, VPs, managing directors, marketing and sales heads/directors, marketing managers, regional/area sales managers, and bioinformatics scientists. Primary demand-side sources included personnel from pharmaceutical and biotechnology companies, hospitals, diagnostic laboratories, and academic and research institutes.

      A breakdown of the primary respondents is provided below:

      Bioinformatics Market Size, and Share

      *Others include sales managers, marketing managers, and product managers.
      Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the bioinformatics market was determined after data triangulation using the two approaches outlined below. After each approach was completed, the weighted average of the two approaches was calculated based on the level of assumptions used in each approach.

      Bioinformatics Market : Top-Down and Bottom-Up Approach

      Bioinformatics Market Top Down and Bottom Up Approach

      Data Triangulation

      The size of the bioinformatics market was estimated through segmental extrapolation using the bottom-up approach. The methodology is as follows:

      • Revenue information of individual companies was gathered from public sources and databases.
      • The share of leading players in the bioinformatics market was obtained from secondary sources to the extent available. In certain cases, shares of bioinformatics businesses have been ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach and strength. 
      • Individual shares or revenue estimates were validated through interviews with experts.
      • The total revenue in the bioinformatics market was determined by extrapolating the market share data of major companies.

      Market Definition

      Bioinformatics is the application of computer technology to the management and analysis of biological data. It encompasses the storage, analysis, and dissemination of biological data. Bioinformatics uses computer programs for a variety of applications, including determining gene and protein functions, establishing evolutionary relationships, and predicting the three-dimensional shapes of proteins.

      Key Stakeholders

      • Bioinformatics software and service providers
      • Academic & research institutes
      • Clinical & diagnostic laboratories
      • Hospitals & healthcare providers
      • Contract research organizations (CROs)
      • Distributors and suppliers of bioinformatics software and services
      • Pharmaceutical & biotechnology companies
      • Market research and consulting firms
      • Venture capitalists

      Report Objectives

      • To define, describe, and forecast the bioinformatics market based on offering, function, use case, sector, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall bioinformatics market
      • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa.
      • To profile the key players and analyze their market share and core competencies2
      • To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall bioinformatics market
      • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

      • Company Information
      • Detailed analysis and profiling of additional market players (up to 5)

      Product Analysis

      • Further breakdown of the Rest of Asia Pacific market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
      • Further breakdown of the Rest of Europe bioinformatics market into Russia, Austria, Finland, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries

      Get the Full Bioinformatics Market Report

      Full forecast, segment splits, and company analysis for all Bioinformatics Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status